Cancer Vaccine

NCI grant to support its development of cancer vaccines using analog epitopes

Published in Cancer Weekly, August 26th, 2003

Epimmune, Inc., (EPMN) announced it had received a grant from the National Cancer Institute (NCI), National Institutes of Health (NIH) to support continued epitope analog identification and preclinical development of multiepitope, analog-based cancer vaccines.

The grant has a total potential value of approximately $0.6 million over 2 years. The activities funded by this grant complement current studies and phase I/II clinical trials the company is conducting by providing analog epitopes that extend vaccine coverage to larger segments of the population. The grant was made under the NCI's Flexible System to Advance Innovative Research for Cancer Drug Discovery by Small...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry